ArticleFrontiers in oncology2026
Case Report: Spatially fractionated radiation therapy for local recurrence after prior radiotherapy in advanced right-sided small cell lung cancer with mediastinal lymph node metastases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 63-year-old male patient was admitted to the Affiliated Hospital of Jiangsu University on December 26, 2025, with a diagnosis of local recurrence in the mediastinal metastatic lymph nodes after radiotherapy, four years following the initial diagnosis of right-sided lung cancer. The patient was diagnosed with advanced small cell lung cancer of the right lung (cT3N3M1) and had previously received a combination of radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Despite these treatments, the disease continued to progress, with resistance to both chemotherapy and immunotherapy, accompanied by widespread metastases. Palliative radiotherapy was administered for mediastinal lymph node enlargement starting July 2, 2025 (P_GTVn: 48 Gy/12 Fx). A follow-up CT scan on December 26, 2025, confirmed local in-situ recurrence of multiple mediastinal lymph nodes, accompanied by tracheal and superior vena cava compression and stenosis, indicating progressive disease (PD). From January 6, 2026, the patient underwent Spatially Fractionated Radiation Therapy (SFRT) targeted at the mediastinal metastatic lymph nodes, with a total dose of 30 Gy in 6 fractions, combined concurrently with atezolizumab immunotherapy. After five fractions of radiotherapy, follow-up computed tomography showed that the tumor volume decreased from 146 ml to 27 ml, representing a tumor regression rate of over 80%. Significant relief of left main bronchus compression was observed. No obvious radiation-related adverse events were noted during treatment or subsequent follow-up. Long-term efficacy requires further observation and evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.